Zealand Pharma has entered into a global license and development agreement with Novo Nordisk to commercialise its low blood sugar therapy, Zegalogue®(dasiglucagon), for injection. The deal, which involves a DKK 25 M (US$3.3 M) upfront payment as well as DKK265 M (US$35.3 M) in milestones, will provide Novo with responsibility for the worldwide net sales of Zegalogue® whilst Zealand will take care of certain planned regulatory, development and manufacturing activities to support further development and approvals outside of the US.